Echocardiographic changes on GLP-1 — my results so far

VendorMark said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

josh_phd_bmore said:

I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

VendorMark said:

I want to bring up the cardiovascular angle on cardiovascular risk.

6 month update on cardiovascular risk: down 40 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

james_edin said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

Moderator note: a couple of off-topic posts removed. Thread quality here is what the rules are for. Keep it up.